UVA1 Phototherapy in Patients with Scleroderma-Related Raynaud’s Phenomenon


About this study

The purpose of this study is to to evaluate patients undergoing the FDA-approved UVA1 phototherapy for systemic sclerosis pre, post, and during treatment for changes in their Raynaud’s phenomenon (RP) burden, digital ulcerations, and piecemeal necrosis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosis compatible with the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis.
  • Significant Raynaud’s Phenomenon (RP) burden despite traditional pharmacotherapy.

Exclusion Criteria: 

  • Current smoker.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Jason Sluzevich, M.D.

Open for enrollment

Contact information:

Breanna Cane

(904) 953-3551


More information


Publications are currently not available

Mayo Clinic Footer